Biomea Fusion Inc Covalent Menin Inhibitor BMF-219's Activity in Diabetes as Presented at the 82nd American Diabetes Association Annual Conference Transcript
Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Covalent Menin Inhibitor BMF-219's Activity in Diabetes as presented at the 82nd American Diabetes Association Annual Meeting. (Operator Instructions) I would now like to hand the conference over to your host, Ramses Erdtmann. Please go ahead.
Thank you, Operator. Good morning and thank you for dialing in. My name is Ramses Erdtmann. I'm the COO, President, and Co-founder of Biomea.
With me on the call today and available to answer questions are our CEO and Chairman, Tom Butler, also Co-founder of Biomea; as well as our CMO, Dr. Steve Morris; our Senior Medical Director, Dr. Sanchita Mourya; and our Associate Director of Translational Research, Priyanka Somanath.
A few words about these team members. Let me start with Steve who joined our team about two years ago first as a consultant. Steve is an internist and medical oncologist. He brings over 35 years of experience as a clinician and academic.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |